Italy's Private Purchases of GLP-1 Drugs Rose 85.7% in a Year as Endocrinologists Warn About Shared and Counterfeit Pens
Il Sole 24 Ore reported that, according to Italian drug regulator AIFA's OsMed 2025 report, private purchases of GLP-1 and dual GIP/GLP-1 drugs rose 85.7% in volume and 75.8% in spending compared with 2024. At their congress in Rome, members of the Association of Medical Endocrinologists warned about drugs passed to relatives and counterfeits sold online. They pointed to a 31-year-old woman in Padua who fell into a hypoglycemic coma in 2025 after injecting a fake incretin that contained insulin.